FGF2 and cancer: It will be of interest to assess whether such interactions may result in the sequestration of platelet-released FGF2, with a consequent modulation of its bioavailability and biological activity in different thrombosis-prone conditions, including tissue ischemia, wound healing, atherosclerosis, and cancer.